Arcutis Biotherapeutics Inc (OQ:ARQT)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 3027 Townsgate Road, Suite 300
WESTLAKE VILLAGE CA 91361
Tel: N/A
Website: https://arcutis.com
IR: See website
<
Key People
Todd Franklin Watanabe
President, Chief Executive Officer, Director
David W. Osborne
Co-Founder, Chief Technical Officer
Scott L. Burrows
Chief Financial Officer, Principal Accounting Officer
Masaru Matsuda
Senior Vice President, General Counsel
Matthew R. Moore
Senior Vice President, Chief Business Officer
Patricia A. Turney
Senior Vice President - Operations
Patrick Burnett
Chief Medical Officer
Kenneth A. Lock
Chief Commercial Officer
 
Business Overview
Arcutis Biotherapeutics, Inc. is a late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for dermatological diseases with unmet medical needs. It harnesses its dermatology development platform to build therapies against biologically validated targets. Its dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions. The company's lead program, topical roflumilast, has the potential to advance the care for plaque psoriasis of the body and scalp, atopic dermatitis and seborrheic dermatitis. It is developing roflumilast cream for the treatment of plaque psoriasis, including psoriasis in intertriginous regions, such as the groin, axillae and inframammary areas, as well as atopic dermatitis. It is also developing ARQ-252 is topical cream formulation of a potent and selective small molecule inhibitor of JAK1 and is developing it for chronic hand eczema and vitiligo.
Financial Overview
For the six months ended 30 June 2022, Arcutis Biotherapeutics Inc revenues was not reported. Net loss increased 69% to $131.7M. Higher net loss reflects General and administrative - Balancing increase from $16.6M to $41M (expense), Research and development - Balancing val increase of 49% to $72.8M (expense), Stock-based Compensation in R&D increase of 65% to $6M (expense).
Employees: 147 as of Dec 31, 2021
Reporting Currency: U.S. Dollars
Enterprise value: $861.71M as of Jun 30, 2022
Annual revenue (TTM): $0.00M as of Jun 30, 2022
EBITDA (TTM): -$256.26M as of Jun 30, 2022
Net annual income (TTM): -$260.04M as of Jun 30, 2022
Free cash flow (TTM): -$212.15M as of Jun 30, 2022
Net Debt Last Fiscal Year: N/A
Shares outstanding: 59,985,348 as of Aug 3, 2022
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.